TOP TIERMARKET NEWSWIRE

News & sentiment

KURA ONCOLOGY INC (KURA) — News & AI sentiment

KURA ONCOLOGY INC (KURA) news roundup. 1 story in the past week, 15 over 30 days. Average 30-day sentiment is 56.5/100. Recent insider activity (SEC Form 4, 90-day window): 2 purchases totalling $2.4M and 8 sales totalling $1.7M — net buying of $643K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

1

avg sentiment 34/100

30d stories

15

avg sentiment 56.5/100

Insider net (90d)

$643K

2 buys · 8 sells

Congress (90d)

0

0 buys · 0 sells

KURA news in the last 24 hours, 7 days, 30 days and 90 days

How much KURA coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	KURA stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	34/100	KURA headlines →
Last 30 days	15	56.5/100	KURA headlines →
Last 90 days	70	56.3/100	KURA headlines →

Latest stories on KURA

Kura Sushi price target lowered to $36 from $59 at Citi

The Fly34 · bearishanalyst

2d ago

Citizens reiterates Kura Oncology stock rating on diabetes data

Investing.com Analyst Ratings50 · neutralanalyst

Oct 14

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Seeking Alpha58 · neutralproduct/pr

Oct 13

Kura and Caspian set a Phase 1 path for KO-7246 after EASD data showed sustained glucose control in preclinical models October 13, 2026

MarketChameleon63 · neutralproduct/pr

Oct 13

Kura Oncology, Caspian outline KO-7246 development strategy in diabetes

The Fly58 · neutralproduct/pr

Oct 13

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

GlobeNewswire61 · neutralproduct/pr

Oct 13

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

StockTitan58 · neutralproduct/pr

Oct 13

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Business Insider56 · neutralproduct/pr

Oct 7

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

GlobeNewswire53 · neutralproduct/pr

Oct 7

UBS reiterates Kura Oncology stock rating on strong launch metrics

Investing.com Analyst Ratings61 · neutralanalyst

Oct 5

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire50 · neutralgeneral

Oct 2

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Insider50 · neutralgeneral

Oct 2

This biotech making precision medicines for cancer could nearly triple, says JPMorgan

CNBC67 · bullishanalyst

Oct 1

JPMorgan initiates Kura Oncology stock with overweight rating

Investing.com Analyst Ratings61 · neutralanalyst

Oct 1

Kura Oncology’s KO-7246 shows positive results as menin inhibitor in diabetes

The Fly67 · bullishproduct/pr

Sep 29

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 16

Wainwright says Caspian spinout lets Kura refocus on oncology, keeping 50% stake

The Fly56 · neutralm&a

Sep 9

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Yahoo Top48 · neutralgeneral

Sep 9

Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus

TipRanks56 · neutralproduct/pr

Sep 9

Kura Oncology launches Caspian Therapeutics

The Fly59 · neutralgeneral

Sep 9

Kura Oncology, Inc. (KURA) files 8-K

SEC 8-K50 · neutralgeneral

Sep 9

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Business Insider28 · bearishgeneral

Sep 9

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

GlobeNewswire28 · bearishgeneral

Sep 9

Kura Oncology Appoints Jennifer Fulk as New CFO

TipRanks50 · neutralgeneral

Sep 8

Kura Oncology appoints Jennifer Fulk as CFO

The Fly55 · neutralgeneral

Sep 8

Open KURA in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →